Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003

J. Coste, H. W. Reesink*, C. P. Engelfriet & S. Laperche & S. Brown, M. P. Busch, H. T. Cuijpers, R. Elgin, B. Ekermo, J. S. Epstein, O. Flesland, H. E. Heier, G. Henn, J. M. Hernandez, I. K. Hewlett, C. Hyland, A. J. Keller, T. Krusius, S. Levicnik-Stezina, G. Levy, C. K. Lin, A. R. Margaritis, L. Muylle, C. Neiderhauser, S. Pastila, J. Pillonel, J. Pineau, C. L. van der Poel, C. Politis, W. K. Roth, S. Sauleda, C. R. Seed, D. Sondag-Thull, S. L. Stramer, M. Strong, E. C. Vamvakas, C. Velati, M. A. Vesga & A. Zanetti

[1]  S. Glynn,et al.  A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors , 2005, Transfusion.

[2]  A. Zanetti,et al.  Residual risk of transfusion‐transmitted HCV and HIV infections by antibody‐screened blood in Italy , 2002, Transfusion.

[3]  M. Bissell.  Detection of HIV-1 and HCV Infections Among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing , 2006 .

[4]  Sally Caglioti,et al.  Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. , 2004, The New England journal of medicine.

[5]  M. Busch,et al.  Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? , 2004, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[6]  H. Reesink,et al.  Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology , 2002, Vox sanguinis.

[7]  M. Kainer,et al.  HIV-1 and HCV infections among antibody-negative blood donors. , 2004, The New England journal of medicine.

[8]  M. Wadhwa,et al.  Cytokine levels as performance indicators for white blood cell reduction of platelet concentrates , 2002, Vox sanguinis.

[9]  E. Seifried,et al.  NAT for HBV and anti‐HBc testing increase blood safety , 2002, Transfusion.

[10]  F. Denis,et al.  Évolution des stratégies vaccinales et couverture vaccinale contre l’hépatite B en France, pays de faible endémie , 2004 .

[11]  G. Schreiber,et al.  Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection , 2003, Transfusion.

[12]  D. Prati,et al.  An estimate of the current risk of transmitting blood‐borne infections through blood transfusion in Italy , 2002, British journal of haematology.

[13]  S. Kleinman,et al.  The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. , 1997, Transfusion medicine reviews.

[14]  S. Stramer,et al.  Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population , 2002, Transfusion.

[15]  S. Glynn,et al.  Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti‐HBc: implications for future HBV screening policy , 2004, Transfusion.